The activation of the PI3K/AKT/mTOR pathway has been reported in AML cells,13, 33 and targeting this signaling pathway has demonstrated beneficial therapeutic effects on AML both in vitro and in vivo.13, 34. This evidence concerns the gene AKT1 and acute myeloid leukemia.